What is the most effective first‑line oral medication for herpes simplex virus (HSV) infection and its recommended dosing regimen?

Best Herpes Medication

For first-episode genital herpes, valacyclovir 1 g orally twice daily for 7-10 days is the best choice, offering equivalent efficacy to acyclovir with superior convenience and adherence. 1

First-Line Oral Antivirals for HSV Infection

The three FDA-approved oral antivirals—acyclovir, valacyclovir, and famciclovir—all provide clinical benefit for HSV infections, but they differ significantly in dosing convenience. 1

For First Clinical Episode (Initial Outbreak)

Valacyclovir is preferred due to its twice-daily dosing, which improves adherence while maintaining equivalent efficacy to acyclovir:

• Valacyclovir 1 g orally twice daily for 7-10 days 1, 2
• Acyclovir 400 mg orally three times daily for 7-10 days 1, 2
• Famciclovir 250 mg orally three times daily for 7-10 days 1

Valacyclovir achieves 3-5 times higher acyclovir blood levels than oral acyclovir due to superior bioavailability, allowing less frequent dosing without sacrificing efficacy. 3, 4 Clinical trials in 643 patients demonstrated that twice-daily valacyclovir matched five-times-daily acyclovir for viral shedding duration, healing time, and pain resolution. 3

Treatment should continue beyond 10 days if lesions have not completely healed. 1, 2

Recurrent Episodes: Episodic vs. Suppressive Therapy

Episodic Treatment (For Infrequent Recurrences)

When initiated during prodrome or within 1 day of lesion onset, episodic therapy shortens outbreak duration. 1, 5 Patients should keep medication on hand to self-initiate treatment at first symptoms. 1, 2

Preferred regimens for convenience:

• Valacyclovir 500 mg orally twice daily for 3-5 days (FDA-approved 3-day regimen) 1, 4, 5
• Acyclovir 800 mg orally twice daily for 5 days 1
• Famciclovir 125 mg orally twice daily for 5 days 1

Suppressive Therapy (For ≥6 Recurrences Per Year)

Daily suppressive therapy reduces recurrence frequency by ≥75% and decreases asymptomatic viral shedding, potentially reducing transmission risk. 1, 2

Recommended daily regimens:

• Valacyclovir 500 mg orally once daily (most convenient; less effective if ≥10 episodes/year) 1
• Valacyclovir 1000 mg orally once daily 1
• Acyclovir 400 mg orally twice daily 1, 2
• Famciclovir 250 mg orally twice daily 1, 2

Valacyclovir is the only antiviral FDA-approved for once-daily suppressive dosing, making it the most practical option for long-term adherence. 4

Safety has been documented for continuous acyclovir use up to 6 years and valacyclovir/famciclovir up to 1 year. 1, 2 After 1 year of suppression, discontinue therapy temporarily to reassess recurrence frequency, as episodes naturally decrease over time in many patients. 1, 2

HSV-1 Oral/Labial Herpes

The same medications and dosing strategies apply to oral HSV-1 infection, though this has been studied less comprehensively than genital HSV-2. 6, 2

For recurrent herpes labialis:

• Valacyclovir 500-1000 mg twice daily for 3-5 days 2, 5
• Acyclovir 400 mg three times daily for 5 days 2, 5
• Topical acyclovir 5% cream (less effective than systemic therapy but acceptable for mild cases) 7, 5

Severe Disease Requiring Hospitalization

For disseminated HSV, encephalitis, pneumonitis, hepatitis, or CNS complications:

• Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days (or until clinical resolution) 1, 2

Recent evidence from a 2026 trial of 94 patients with HSV encephalitis found that adjunct dexamethasone (10 mg/kg IV four times daily for 4 days) plus acyclovir did not improve verbal memory outcomes compared to acyclovir alone, though it had an acceptable safety profile. 8 Therefore, acyclovir monotherapy remains standard for HSV encephalitis. 8

Special Populations

Immunocompromised/HIV-Infected Patients

These patients may require higher doses and longer treatment courses. 1, 2

• Acyclovir 400 mg orally 3-5 times daily until complete resolution 2
• Famciclovir 500 mg twice daily (effective in HIV patients) 2
• For severe disease: Acyclovir 5 mg/kg IV every 8 hours 2

Caution: Very high-dose valacyclovir (8 g/day) has been associated with hemolytic-uremic syndrome/thrombotic thrombocytopenic purpura in immunocompromised patients; standard therapeutic doses remain safe. 2

Pregnancy

Acyclovir and valacyclovir are considered safe in pregnancy for treating symptomatic HSV infection. 1 Specific pregnancy management should follow obstetric guidelines for preventing neonatal transmission.

Critical Limitations of All Antivirals

• Antivirals do not eradicate latent HSV and cannot prevent future recurrences after discontinuation. 1, 2
• Antivirals do not eliminate asymptomatic viral shedding, so transmission risk persists even without visible lesions. 1, 2
• Topical acyclovir is substantially less effective than oral therapy and should be avoided. 1

Emerging Therapies

Helicase-primase inhibitors (HPIs) represent a promising new drug class with a novel mechanism targeting viral DNA replication machinery, showing high efficacy and potential to overcome acyclovir resistance. 9 However, these remain investigational and are not yet FDA-approved for clinical use. 9

Common Pitfalls to Avoid

• Do not use topical acyclovir for genital herpes—it provides minimal benefit compared to systemic therapy. 1
• Do not delay episodic treatment—efficacy depends on starting within 1 day of symptom onset. 1, 5
• Do not continue suppressive therapy indefinitely without reassessment—recurrence frequency often decreases naturally over time. 1, 2
• Do not use valacyclovir 500 mg once daily for patients with ≥10 episodes/year—higher doses are needed. 1